A sharp decline in U.S. overdose deaths appears increasingly tied to a disruption in the global fentanyl supply chain – an outcome that new research suggests may stem in part from intensified pressure on Chinese chemical suppliers. The findings, published Thursday in Science, enter a long-running debate over what finally reversed a drug crisis that pushed annual overdose deaths above 100,000 during the Biden administration. Fatalities began falling in mid-2023 and dropped more sharply thereafter, a trend that has continued under Donald Trump, who has long-framed fentanyl trafficking as a national-security threat and used tariffs, border enforcement and overseas interdictions as leverage. While public-health officials have pointed to billions spent on addiction treatment, naloxone distribution and domestic law enforcement, the research places renewed emphasis on a crackdown by Beijing – specifically, efforts to prevent fentanyl from being manufactured at all. The paper concludes that the illicit fentanyl market experienced a significant supply contraction, “possibly tied to Chinese government actions,” citing falling purity in seized drugs, reduced seizure volumes and online reports of shortages. The findings align with arguments long advanced by Trump and his advisers: that pressuring China’s chemical sector was central to choking off supply. “This demonstrates how influential China can be and how much they can help us […]